Thus, HS and tau interaction is a crucial step in the prion-like spread of tau pathology and can be targeted for novel therapeutics for tauopathies like Alzheimer’s disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.